今日の臨床サポート

肺非結核性抗酸菌症

関連論文:
img  35:  Clinical and molecular analysis of macrolide resistance in Mycobacterium avium complex lung disease.
 
著者: David E Griffith, Barbara A Brown-Elliott, Brett Langsjoen, Yansheng Zhang, Xi Pan, William Girard, Kenwyn Nelson, James Caccitolo, Julio Alvarez, Sara Shepherd, Rebecca Wilson, Edward A Graviss, Richard J Wallace
雑誌名: Am J Respir Crit Care Med. 2006 Oct 15;174(8):928-34. doi: 10.1164/rccm.200603-450OC. Epub 2006 Jul 20.
Abstract/Text RATIONALE: The clinical features and outcome of macrolide-resistant Mycobacterium avium complex (MAC) lung disease are not known.
OBJECTIVES: Characterize patients, treatment, and isolates in macrolide-resistant MAC lung disease.
METHODS: Retrospective chart review, susceptibility testing, molecular fingerprinting, and DNA sequence analyses of resistant MAC isolates.
MEASUREMENTS AND MAIN RESULTS: We identified 51 patients over a 15-yr period with clarithromycin-resistant MAC (minimum inhibitory concentration (MIC)>or=32 microg/ml) lung disease at a single referral center. Twenty-four (47%) patients had nodular disease with bronchiectasis and 27 (53%) had upper lobe cavitary disease. Most patients (77%) had M. intracellulare. Sequencing of the 23S r-RNA gene showed 49 of 51 isolates (96%) with the expected mutation in adenine 2058 or 2059. Risk factors for resistance included macrolide monotherapy or combination with a quinolone only (39/51 or 76%). Macrolide resistance developed in 12 of 303 (4.0%) patients started on the American Thoracic Society-recommended two companion drugs, with no risk difference in clarithromycin versus azithromycin and daily versus intermittent therapy. Sputum conversion with macrolide-resistant MAC occurred in 11 of 14 (79%) patients who received more than 6 mo of injectable aminoglycoside therapy and lung resection, compared with 2 of 37 (5%) who did not. The 1-yr mortality in patients who remained culture positive was 34% (13/38) compared with 0% (0/13) of patients who became culture negative (converted).
CONCLUSIONS: Macrolide resistance rarely occurs in patients also receiving ethambutol and a rifamycin. Macrolide-resistant MAC lung disease requires aggressive drug and surgical therapy for cure.

PMID 16858014  Am J Respir Crit Care Med. 2006 Oct 15;174(8):928-34. doi: 10.1164/rccm.200603-450OC. Epub 2006 Jul 20.
戻る

さらなるご利用にはご登録が必要です。

こちらよりご契約または優待日間無料トライアルお申込みをお願いします。

(※トライアルご登録は1名様につき、一度となります)


ご契約の場合はご招待された方だけのご優待特典があります。

以下の優待コードを入力いただくと、

契約期間が通常12ヵ月のところ、14ヵ月ご利用いただけます。

優待コード: (利用期限:まで)

ご契約はこちらから